Ovarian Cancer
Conditions
Keywords
Ovarian Cancer, Conventional chemotherapy, blood stem cells, autologous blood transfusion
Brief summary
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
Detailed description
Study design:In this prospective, single-center,non-randomised controlled study, patients with ovarian cancer were divided into two groups. The patients in the experimental group received autologous blood transfusion containing hematopoietic stem cells 1 day after conventional chemotherapy, while the control group only received conventional chemotherapy. Case selection: Patients with primary ovarian cancer,ovarian cancer confirmed by histopathology, and three weeks of platinum-containing regimen chemotherapy. Primary end point: 1)incidence and duration of grade 3/4 neutropenia in patients;2)hematopoietic reconstitution time in patients. Secondary endpoints: 1)the rate of reduction in chemotherapy dose and postponement of the course for chemotherapy;2) Incidence of febrile neutropenia (FN);3)Safety of hematopoietic stem cell reinfusion therapy (adverse events). Safety assessment: laboratory safety testing, including platelet count,white blood cell and hemoglobin. Evaluation of adverse events: infection, neutropenic fever, hypocalcemia,anemia and thrombocytopenia,bone pain, etc.
Interventions
Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Sponsors
Chongqing University Cancer Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 18-60 years old; * there are chemotherapy indicators for ovarian cancer; * ovarian cancer diagnosed by histopathology; * recurrent and metastatic ovarian cancer; * the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; * the expected survival time was more than 3 months; * pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative; * all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment; * the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations; * bone marrow function is good,ability to perform stem cell mobilisation and collection.
Exclusion criteria
* patients with bone marrow disease; * central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology; * patient has severe cardiac insufficiency; * previous history of allogeneic stem cell transplantation or organ transplantation; * patients with active bleeding and autoimmune thrombocytopenic purpura; * patients with chemotherapy contraindications; * positive for human immunodeficiency virus (HIV); * acute or chronic active hepatitis B or hepatitis C infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Grade 3-4 neutropenia | 8 months | Incidence of Grade 3-4 neutropenia |
| Time to reconstruct haematopoietic function | 6 months | Time to reconstruct haematopoietic function |
| Incidence of febrile neutropenia (FN) | 8 months | Incidence of febrile neutropenia (FN) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the rate of postponement of the course for chemotherapy | 8 months | the rate of postponement of the course for chemotherapy |
| reduction in chemotherapy dose | 6 months | reduction in chemotherapy dose |
| Incidence of hematopoietic stem cell reinfusion treatment Adverse Events [Safety and Tolerability] | 3 months | Incidence of hematopoietic stem cell reinfusion treatment Adverse Events \[Safety and Tolerability\] |
Countries
China
Contacts
CONTACTDongling Zou, M.D.
PRINCIPAL_INVESTIGATORDongling Zou, M.D.
Chongqing University Cancer Hospital
Outcome results
None listed